CERTIFICATE NUMBER:
401-24/2025-5
CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER(1)
, (2)
Part 1
Issued following an inspection in accordance with Art. 111(5) of Directive 2001/83/EC as amended Art. 63 of Regulation (EU) 536/2014 as amended
The competent authority of Slovenia confirms the following:
The manufacturer: Lek Pharmaceuticals d.d.
Site address:
Verovskova Ulica 57, Ljubljana, 1526, Slovenia
OMS Organisation Id. / OMS Location Id.: ORG-100000695 / LOC-100002319
DUNS Number:
36-470-4288
Has been inspected under the national inspection programme in connection with manufacturing authorisation no.
800-6/2024-14
in accordance with Art. 61 of Regulation (EU) No 536/2014 and Art. 40 of Directive 2001/83/EC.
From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on
2025-11-18
, it is considered that it complies with:
The principles and guidelines of Good Manufacturing Practice laid down in Directive (EU) 2017/1572 and/or Commission Delegated Regulation (EU) 2017/1569, as reflected by the product categories stated in Part 2. (3)
This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. Updates to restrictions or clarifying remarks can be identified through the EudraGMDP website (https://eudragmdp.ema.europa.eu/). This certificate is valid only when presented with all pages and both Parts 1 and 2.
The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.
__________________________________________________________________________________________________________________________
(1) The certificate referred to in paragraph Art. 111(5) of Directive 2001/83/EC and Art. 15 of Directive 2001/20/ECis also applicable to importers. (2) Guidance on the interpretation of this template can be found in the Interpretation of the Union format for GMP certificate. (3) These requirements fulfil the GMP recommendations of WHO.
Part 2
Human Medicinal Products
Human Investigational Medicinal Products
1 MANUFACTURING OPERATIONS
1.1 Sterile products
1.1.1 Aseptically prepared (processing operations for the following dosage forms)
1.1.1.2 Lyophilisates Special Requirements: 7 Other: Prostaglandines, Cytokines, Cytotoxics/Cytostatics, Immunosuppresives(en) 1.1.1.4 Small volume liquids Special Requirements: 7 Other: Hormones or Substance with Hormonal Activity, Cytotoxics/Cytostatics(en) 1.1.2 Terminally Sterilised (processing operations for the following dosage forms)
1.1.2.3 Small volume liquids Special Requirements: 7 Other: Hormones or Substance with Hormonal Activity(en) 1.1.3 Batch certification
1.2 Non-sterile products
1.2.1 Non-sterile products (processing operations for the following dosage forms)
1.2.1.1 Capsules, hard shell Special Requirements: 7 Other: Cytotoxics/Cytostatics, Immunosuppresives(en) 1.2.1.5 Liquids for external use Special Requirements: 7 Other: Hormones or Substance with Hormonal Activity(en) 1.2.1.6 Liquids for internal use Special Requirements: 7 Other: Hormones or Substance with Hormonal Activity(en) 1.2.1.8 Other solid dosage forms: granules, pellets, micropellets, granulates, powders, mini tablets(en) 1.2.1.13 Tablets Special Requirements: 7 Other: Hormones or Sustance with Hormonal Activity, Cytotoxics/Cytostatics, Immunosuppresives(en) 1.2.2 Batch certification
1.3 Biological medicinal products (list of product types)
1.3.1 Biological medicinal products (list of product types)
1.3.1.2 Immunological products 1.3.1.5 Biotechnology products 1.3.2 Batch Certification (list of product types)
1.3.2.2 Immunological products 1.3.2.5 Biotechnology products
1.5 Packaging
1.5.1 Primary Packaging
1.5.1.1 Capsules, hard shell Special Requirements: 7 Other: Cytotoxics/Cytostatics, Immunosuppresives(en) 1.5.1.5 Liquids for external use Special Requirements: 7 Other: Hormones or Substance with Hormonal Activity(en) 1.5.1.6 Liquids for internal use Special Requirements: 7 Other: Hormones or Substance with Hormonal Activity(en) 1.5.1.8 Other solid dosage forms: granules, pellets, micropellets, granulates, powders, mini tablets(en) 1.5.1.13 Tablets Special Requirements: 7 Other: Hormones or Substance with Hormonal Activity, Cytotoxics/Cytostatics, Immunosuppresives(en) 1.5.2 Secondary packaging
1.6 Quality control testing
1.6.1 Microbiological: sterility
1.6.2 Microbiological: non-sterility
1.6.3 Chemical/Physical
1.6.4 Biological
2 IMPORTATION OF MEDICINAL PRODUCTS
2.1 Quality control testing of imported medicinal products
2.1.1 Microbiological: sterility
2.1.2 Microbiological: non-sterility
2.1.3 Chemical/Physical
2.1.4 Biological
2.2 Batch certification of imported medicinal products
2.2.1 Sterile products
2.2.1.1 Aseptically prepared 2.2.1.2 Terminally sterilised 2.2.2 Non-sterile products
2.2.3 Biological medicinal products
2.2.3.2 Immunological products 2.2.3.5 Biotechnology products 2.2.3.8 Other: Lyophilised Bacterial Lysate(en)
2.3 Other importation activities
2.3.1 Site of physical importation
2.3.2 Importation of intermediate which undergoes further processing
2.3.3 Biological active substance
2.3.4 Other: Herbal Products(en)
Clarifying remarks (for public users):